Imugene (ASX:IMU)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Imugene.
RELATED STOCKHEAD STORIES
Health Check: Bargain hunters flock to 4D Medical’s discounted raising
Health Check: Emvision’s stroke detector takes to the skies
Health Check: Star biotech stocks are going cheap – or cheaper than they were
Health Check: Half-price sale as brokers ring the bell on Neuren shares
Biocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapy
ASX Lunch Wrap: ASX battles for momentum after Nasdaq’s Friday bounce
Health Check: Local biotech starred in 2024, but the rising tide did not lift all boats
ASX Small Caps Lunch Wrap: Stocks flashing red this morning, as all eyes glued on RBA, Vauban
Closing Bell: ASX dips as AGL stalls; Talga skyrockets after Sweden approves graphite mine
ASX Health Stocks: Imugene reveals promise in lymphoma trial, stock soars 27pc
Top 10 at 11: Robot sentries, big deals and exploration are today’s headline makers
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
Market Highlights: Nvidia loses top spot to Microsoft on ‘Triple Witching’ day, and 5 small caps to watch
